Fibromyalgia. Fibromyalgia
Conditions
Interventions
Intervention 1: Duloxetin 30 mg once daily and if tolerate increase to 60 mg once daily for 3 next week. Intervention 2: Pregabalin 75 mg once daily and after 1 week if tolerate increase to 75 mg twic
Treatment - Drugs
Duloxetin 30 mg once daily and if tolerate increase to 60 mg once daily for 3 next week.
Pregabalin 75 mg once daily and after 1 week if tolerate increase to 75 mg twice daily for 3 next 3 week
Sponsors
Vice Chancellor for Research of Iran University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: fibromyalgia patients; age between 18 to 65; Exclusion criteria: receiving Duloxetine, Pregabalin and Gabapentin with other antidepressants during the 12 weeks before entering the study; pregnancy or have a plan to become pregnant during the study; underlying rheumatic disease, cancer, and other diseases that can cause chronic pain which has not been defined in the fibromyalgia syndrome; having a job or duties which need high concentration or alertness; use of MAOI (monoamine oxidase inhibitors) within 14 days before study; chronic liver disease, severe renal failure and uncontrolled narrow-angle glaucoma; history of hypersensitivity to Pregabalin and its components
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pain. Timepoint: At the begining and 4 weeks after treatment. Method of measurement: FIQ and WPI questionaire.;Depression. Timepoint: At the begining and 4 weeks after treatment. Method of measurement: SF-12 and becks questionaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| Drug adverse reactions. Timepoint: 1 week after start the drug. Method of measurement: Drug adverse reactions questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Shahrzad Rahmani
Iran University of Medical Science
Outcome results
None listed